STAT4狼疮风险等位基因rs7574865[T]与系统性红斑狼疮患者T细胞中IL-12诱导的IFN-γ生成增加相关
研究纳入52例已行基因分型的系统性红斑狼疮(SLE)患者,检测外周血单个核细胞(PBMC)中STAT4/STAT1磷酸化、总STAT4、STAT1、T-bet水平及IL-12刺激后IFN-γ+细胞频率,并按STAT4风险等位基因携带状态进行关联分析。结果显示,经植物血凝素(PHA)/IL-2预激活后,携带风险等位基因者的CD8+ T细胞STAT4水平升高,IL-12及IFN-α诱导的pSTAT4增加,CD8+与CD4+ T细胞IL-12诱导的IFN-γ生成增强;TYK2抑制剂与JAK2抑制剂分别有效阻断IL-12与IFN-γ诱导的PBMC活化。作者认为该亚组患者可能从JAK抑制剂治疗中获益。
要点
- 静息PBMC中,STAT4风险等位基因与总STAT4、STAT1水平及细胞因子诱导的pSTAT4、pSTAT1均无关。
- PHA/IL-2激活后,携带风险等位基因的SLE患者CD8+ T细胞总STAT4升高,IL-12与IFN-α诱导的pSTAT4增加。
- PHA/IL-2激活后,CD8+与CD4+ T细胞IL-12诱导的IFN-γ生成增强;TYK2i、JAK2i分别有效阻断IL-12、IFN-γ诱导的PBMC活化。
核心结论
- 携带STAT4风险等位基因rs7574865[T]的SLE患者T细胞对IL-12和IFN-α的反应增强。
- 作者认为该亚组患者可能从JAK抑制剂治疗中获益。
研究设计与样本
- 研究纳入52例已行基因分型的SLE患者,分离外周血单个核细胞(PBMC)。
- 用流式细胞术在多种免疫细胞亚群中检测STAT4与STAT1磷酸化、总STAT4、STAT1、T-bet水平及IL-12刺激后IFN-γ+细胞频率,并在PHA/IL-2预激活前后分别检测。
- 将细胞反应与表型与STAT4风险等位基因携带状态做相关性分析;并评估选择性TYK2抑制剂(TYK2i)与JAK2抑制剂(JAK2i)对IL-12或IFN-γ诱导SLE PBMC活化的抑制作用。
主要发现
- 静息PBMC中,STAT4风险等位基因与总STAT4或STAT1水平无关,也与细胞因子诱导的pSTAT4或pSTAT1无关。
- PHA/IL-2激活后,携带STAT4风险等位基因者的CD8+ T细胞STAT4水平升高,IL-12和IFN-α诱导的pSTAT4增加。
- PHA/IL-2激活后,携带风险等位基因者CD8+和CD4+ T细胞中IL-12诱导的IFN-γ生成增强。
- TYK2i与JAK2i分别有效阻断STAT4风险患者PBMC中IL-12与IFN-γ诱导的活化。
关键数值与推荐
- 研究纳入52例已行基因分型的SLE患者。
- 风险等位基因关联分析的对象为STAT4风险等位基因rs7574865[T]携带状态。
- PHA/IL-2预激活后,携带风险等位基因的CD8+ T细胞STAT4水平升高,IL-12和IFN-α诱导的pSTAT4增加,CD8+与CD4+ T细胞IL-12诱导的IFN-γ生成增强。
临床怎么用
- 作者认为携带STAT4风险等位基因rs7574865[T]的SLE患者这一亚组可能从JAK抑制剂治疗中获益。
- 原文报告TYK2i与JAK2i分别有效阻断STAT4风险患者PBMC中IL-12与IFN-γ诱导的活化,原文未据此给出具体用药推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Genetic variants in the transcription factor STAT4 are associated with increased susceptibility to systemic lupus erythematosus (SLE) and a more severe disease phenotype. This study aimed to clarify how the SLE-associated intronic STAT4 risk allele rs7574865[T] affects the function of immune cells in SLE. METHODS: Peripheral blood mononuclear cells (PBMCs) were isolated from 52 genotyped patients with SLE. Phosphorylation of STAT4 (pSTAT4) and STAT1 (pSTAT1) in response to interferon (IFN)-α, IFN-γ or interleukin (IL)-12, total levels of STAT4, STAT1 and T-bet, and frequency of IFN-γ+ cells on IL-12 stimulation were determined by flow cytometry in subsets of immune cells before and after preactivation of cells with phytohaemagglutinin (PHA) and IL-2. Cellular responses and phenotypes were correlated to STAT4 risk allele carriership. Janus kinase inhibitors (JAKi) selective for TYK2 (TYK2i) or JAK2 (JAK2i) were evaluated for inhibition of IL-12 or IFN-γ-induced activation of SLE PBMCs. RESULTS: In resting PBMCs, the STAT4 risk allele was neither associated with total levels of STAT4 or STAT1, nor cytokine-induced pSTAT4 or pSTAT1. Following PHA/IL-2 activation, CD8+ T cells from STAT4 risk allele carriers displayed increased levels of STAT4 resulting in increased pSTAT4 in response to IL-12 and IFN-α, and an augmented IL-12-induced IFN-γ production in CD8+ and CD4+ T cells. The TYK2i and the JAK2i efficiently blocked IL-12 and IFN-γ-induced activation of PBMCs from STAT4 risk patients, respectively. CONCLUSIONS: T cells from patients with SLE carrying the STAT4 risk allele rs7574865[T] display an augmented response to IL-12 and IFN-α. This subset of patients may benefit from JAKi treatment.
引用
- Hagberg N, Joelsson M, Leonard D, et al. The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE. Ann Rheum Dis. 2018. PMID: 29475858. doi:10.1136/annrheumdis-2017-212794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。